Abstract Background The Ad26. COV2. S vaccine is a recombinant, replication-incompetent
human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome …

Background The human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine was
immunogenic, generally well tolerated, and effective against HPV-16 or HPV-18 infections …

Background The aim of this interim analysis of a large, international phase III study was to
assess the efficacy of an AS04 adjuvanted L1 virus-like-particle prophylactic candidate …

Background Efficacious vaccines are urgently needed to contain the ongoing coronavirus
disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome …

Background Cervical intraepithelial neoplasia grade 2 or greater (CIN2+) is the surrogate
endpoint used in licensure trials of human papillomavirus (HPV) vaccines. Vaccine efficacy …

Abstract The Ad26. COV2. S vaccine,–has demonstrated clinical efficacy against
symptomatic COVID-19, including against the B. 1.351 variant that is partially resistant to …

Abstract Background The Ad26. COV2. S vaccine was highly effective against severe–
critical coronavirus disease 2019 (Covid-19), hospitalization, and death in the primary phase …

Importance Control of the global COVID-19 pandemic will require the development and
deployment of safe and effective vaccines. Objective To evaluate the immunogenicity of the …

Durability of Response after Ad26. COV2. S Vaccination In this study, investigators
measured immune responses in 20 participants who had received either one or two doses …

Background We evaluated the efficacy of the human papillomavirus HPV-16/18 AS04-
adjuvanted vaccine against non-vaccine oncogenic HPV types in the end-of-study analysis …